Additivity in the Analysis and Design of HIV Protease Inhibitors

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2009 Feb 6

PMID 19193159

Citations 9

Authors

Robert N Jorissen

G S Kiran Kumar Reddy

Akbar Ali

Michael D Altman

Sripriya Chellappan

Saima G Anjum

Bruce Tidor

Celia A Schiffer

Tariq M Rana

Michael K Gilson

Affiliations

Soon will be listed here.

Abstract

We explore the applicability of an additive treatment of substituent effects to the analysis and design of HIV protease inhibitors. Affinity data for a set of inhibitors with a common chemical framework were analyzed to provide estimates of the free energy contribution of each chemical substituent. These estimates were then used to design new inhibitors whose high affinities were confirmed by synthesis and experimental testing. Derivations of additive models by least-squares and ridge-regression methods were found to yield statistically similar results. The additivity approach was also compared with standard molecular descriptor-based QSAR; the latter was not found to provide superior predictions. Crystallographic studies of HIV protease-inhibitor complexes help explain the perhaps surprisingly high degree of substituent additivity in this system, and allow some of the additivity coefficients to be rationalized on a structural basis.

Citing Articles

Additivity-based design of the strongest possible turkey ovomucoid third domain inhibitors for porcine pancreatic elastase (PPE) and Streptomyces griseus protease B (SGPB).

Qasim M, Wang L, Qasim S, Lu S, Lu W, Wynn R FEBS Lett. 2013; 587(18):3021-6.

PMID: 23892073 PMC: 3784018. DOI: 10.1016/j.febslet.2013.07.029.

A combined 3D-QSAR and docking studies for the In-silico prediction of HIV-protease inhibitors.

Ul-Haq Z, Usmani S, Shamshad H, Mahmood U, Ahsan Halim S Chem Cent J. 2013; 7(1):88.

PMID: 23683267 PMC: 3660290. DOI: 10.1186/1752-153X-7-88.

Characterization of small molecule binding. I. Accurate identification of strong inhibitors in virtual screening.

Ding B, Wang J, Li N, Wang W J Chem Inf Model. 2012; 53(1):114-22.

PMID: 23259763 PMC: 3584174. DOI: 10.1021/ci300508m.

Site-Specific Fragment Identification Guided by Single-Step Free Energy Perturbation Calculations.

Raman E, Vanommeslaeghe K, MacKerell Jr A J Chem Theory Comput. 2012; 8(10):3513-3525.

PMID: 23144598 PMC: 3490637. DOI: 10.1021/ct300088r.

Composite multi-parameter ranking of real and virtual compounds for design of MC4R agonists: renaissance of the Free-Wilson methodology.

Nilsson I, Polla M J Comput Aided Mol Des. 2012; 26(10):1143-57.

PMID: 23053734 DOI: 10.1007/s10822-012-9605-7.

References

King N, Prabu-Jeyabalan M, Nalivaika E, Wigerinck P, de Bethune M, Schiffer C . Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol. 2004; 78(21):12012-21. PMC: 523255. DOI: 10.1128/JVI.78.21.12012-12021.2004. View

Greco W, HAKALA M . Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors. J Biol Chem. 1979; 254(23):12104-9. View

Dirlam J, Czuba L, Dominy B, James R, Pezzullo R, Presslitz J . Synthesis and antibacterial activity of 1-hydroxy-1-methyl-1,3-dihydrofuro[3,4-b]quinoxaline 4,9-dioxide and related compounds. J Med Chem. 1979; 22(9):1118-21. DOI: 10.1021/jm00195a022. View

Miller J, Andrews C, Brieger M, Furfine E, Hale M, Hanlon M . Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorg Med Chem Lett. 2006; 16(7):1788-94. DOI: 10.1016/j.bmcl.2006.01.035. View

Prabu-Jeyabalan M, Nalivaika E, Schiffer C . Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure. 2002; 10(3):369-81. DOI: 10.1016/s0969-2126(02)00720-7. View

FREE Jr S, Wilson J . A MATHEMATICAL CONTRIBUTION TO STRUCTURE-ACTIVITY STUDIES. J Med Chem. 1964; 7:395-9. DOI: 10.1021/jm00334a001. View

Ali A, Reddy G, Cao H, Anjum S, Nalam M, Schiffer C . Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. J Med Chem. 2006; 49(25):7342-56. DOI: 10.1021/jm060666p. View

Richman D . HIV chemotherapy. Nature. 2001; 410(6831):995-1001. DOI: 10.1038/35073673. View

King N, Prabu-Jeyabalan M, Nalivaika E, Schiffer C . Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol. 2004; 11(10):1333-8. DOI: 10.1016/j.chembiol.2004.08.010. View

10.

Prabu-Jeyabalan M, King N, Nalivaika E, Heilek-Snyder G, Cammack N, Schiffer C . Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 2006; 50(4):1518-21. PMC: 1426980. DOI: 10.1128/AAC.50.4.1518-1521.2006. View

11.

Matayoshi E, Wang G, Krafft G, Erickson J . Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science. 1990; 247(4945):954-8. DOI: 10.1126/science.2106161. View

12.

Surleraux D, Tahri A, Verschueren W, Pille G, de Kock H, Jonckers T . Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem. 2005; 48(6):1813-22. DOI: 10.1021/jm049560p. View

13.

Chellappan S, Kairys V, Fernandes M, Schiffer C, Gilson M . Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Proteins. 2007; 68(2):561-7. DOI: 10.1002/prot.21431. View

14.

Pauwels R . New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr Opin Pharmacol. 2004; 4(5):437-46. DOI: 10.1016/j.coph.2004.07.005. View

15.

Altman M, Ali A, Reddy G, Nalam M, Anjum S, Cao H . HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc. 2008; 130(19):6099-113. PMC: 3465729. DOI: 10.1021/ja076558p. View

16.

Reddy G, Ali A, Nalam M, Anjum S, Cao H, Nathans R . Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem. 2007; 50(18):4316-28. PMC: 3862176. DOI: 10.1021/jm070284z. View

17.

Chellappan S, Reddy G, Ali A, Nalam M, Anjum S, Cao H . Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des. 2007; 69(5):298-313. DOI: 10.1111/j.1747-0285.2007.00514.x. View

18.

Hoffman B, Cho S, Zheng W, Wyrick S, Nichols D, Mailman R . Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. J Med Chem. 1999; 42(17):3217-26. DOI: 10.1021/jm980415j. View